Hitachi (Proton Therapy)
Hitachi's proton-therapy division — distinct from the broader Hitachi imaging business that became Fujifilm Healthcare in 2021. The proton-therapy business stayed within Hitachi Ltd. and continues under Hitachi High-Tech / Hitachi Industrial Equipment branding. Top-tier proton-therapy vendor globally alongside IBA and Varian / Mevion in the multi-room and single-room categories respectively. Particularly strong installed base in U.S. academic proton centers (MD Anderson, MGH, Mayo, others) where Hitachi's synchrotron-based platform is the canonical multi-room build.
Company history
- 2000s — Hitachi Proton Beam Therapy System enters clinical use.
- 2006 — first U.S. installation at MD Anderson Cancer Center (Houston).
- 2010s — Mayo Clinic, MGH, additional U.S. and global academic proton-therapy centers built on Hitachi platforms.
- 2020s — continued multi-room proton-therapy market; PROBEAT brand evolution.
Product line
- PROBEAT-V — multi-room proton-therapy platform with synchrotron accelerator; pencil-beam-scanning standard.
- PROBEAT earlier-generation systems remain in clinical service at multiple centers.
Distinctive technology
- Synchrotron accelerator — distinct from cyclotron-based competitors (IBA / Mevion / Varian ProBeam). Synchrotron permits energy variation per pulse without absorbers; advantage for clinical workflow and dose flexibility.
- Pencil-beam scanning (PBS) — current clinical standard, deployed across Hitachi multi-room installs.
- Multi-room architecture — typical Hitachi-installed centers serve 3–5 treatment rooms from a single synchrotron, optimizing capital intensity at high-volume academic sites.
Market position
Top-tier multi-room proton-therapy vendor alongside IBA Proteus PLUS. Particularly strong in U.S. academic centers; smaller compact / single-room presence than IBA Proteus ONE or Mevion S250. Direct competitors: IBA (multi-room Proteus PLUS, single-room Proteus ONE), Mevion (single-room), Varian ProBeam.
Refurb posture
- No meaningful refurb market — proton-therapy installed base is small, per-vendor, and program-level. Lifecycle decisions are institutional.
- Service-contract continuity dominates operating economics; OEM-led service is the norm.
Related
- Proton Therapy
- IBA (primary competitor)
- Mevion (single-room competitor)
- Hitachi (imaging division — separate)
- IBA Proteus ONE
- IBA Proteus PLUS
- Brain SRS
- AAPM TG-142 (adapted)
- Rad Onc Physicist